N1-[(1S)-2,2-Dimethyl-1-[[[(1R)-1-phenylethyl]amino]carbonyl]propyl]-N4-hydroxy-2-[3-(2-methyl[1,1'-biphenyl]-4-yl)propyl]-butanediamine

Request For Quotation
N1-[(1S)-2,2-Dimethyl-1-[[[(1R)-1-phenylethyl]amino]carbonyl]propyl]-N4-hydroxy-2-[3-(2-methyl[1,1'-biphenyl]-4-yl)propyl]-butanediamine Suppliers list
Company Name: J & K SCIENTIFIC LTD.  
Tel: 18210857532 18210857532
Email: jkinfo@jkchemical.com
Company Name: 3B Pharmachem (Wuhan) International Co.,Ltd.  
Tel: 18930552037
Email: 3bsc@sina.com
Company Name: Chemsky（shanghai）International Co.,Ltd.  
Tel: 021-50135380
Email: shchemsky@sina.com
Company Name: Sichuan Wei Keqi Biological Technology Co., Ltd.  
Tel: 028-81700200 18116577057
Email: 3003855609@qq.com
Company Name: EMMX Biotechnology LLC  
Tel: 888-539-0666
Email: info@emmx.com

N1-[(1S)-2,2-Dimethyl-1-[[[(1R)-1-phenylethyl]amino]carbonyl]propyl]-N4-hydroxy-2-[3-(2-methyl[1,1'-biphenyl]-4-yl)propyl]-butanediamine manufacturers

  • UK 356618
  • UK 356618 pictures
  • $2260.00
  • 2026-09-12
  • CAS:230961-08-7
  • Purity:
  • Supply Ability: 10g
  • UK-356618
  • UK-356618 pictures
  • 2026-07-01
  • CAS:230961-08-7
  • Min. Order: 1KG
  • Purity: 98%
  • Supply Ability: 1000kg
N1-[(1S)-2,2-Dimethyl-1-[[[(1R)-1-phenylethyl]amino]carbonyl]propyl]-N4-hydroxy-2-[3-(2-methyl[1,1'-biphenyl]-4-yl)propyl]-butanediamine Basic information
Product Name:N1-[(1S)-2,2-Dimethyl-1-[[[(1R)-1-phenylethyl]amino]carbonyl]propyl]-N4-hydroxy-2-[3-(2-methyl[1,1'-biphenyl]-4-yl)propyl]-butanediamine
Synonyms:N1-[(1S)-2,2-Dimethyl-1-[[[(1R)-1-phenylethyl]amino]carbonyl]propyl]-N4-hydroxy-2-[3-(2-methyl[1,1'-biphenyl]-4-yl)propyl]-butanediamine;UK 356618;(2R)-N1-[(1S)-2,2-DiMethyl-1-[[[(1R)-1-phenylethyl]aMino]carbonyl]propyl]-N4-hydroxy-2-[3-(2-Methyl[1,1'-biphenyl]-4-yl)propyl]butanediaMide;PF-03890101;(2R)-N1-[(1S)-2,2-Dimethyl-1-({[(1R)-1-phenylethyl]amino}carbonyl)propyl]-2-{3-[(3-methyl-4-phenyl)-phenyl]propyl}-(N4-hydroxy)butanediamide;UK 356618 - PF 03890101;Butanediamide, N1-[(1S)-2,2-dimethyl-1-[[[(1R)-1-phenylethyl]amino]carbonyl]propyl]-N4-hydroxy-2-[3-(2-methyl[1,1'-biphenyl]-4-yl)propyl]-, (2R)-
CAS:230961-08-7
MF:C34H43N3O4
MW:557.72
EINECS:
Product Categories:Aromatics;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pfizer Compounds;Pharmaceuticals
Mol File:230961-08-7.mol
N1-[(1S)-2,2-Dimethyl-1-[[[(1R)-1-phenylethyl]amino]carbonyl]propyl]-N4-hydroxy-2-[3-(2-methyl[1,1'-biphenyl]-4-yl)propyl]-butanediamine Structure
N1-[(1S)-2,2-Dimethyl-1-[[[(1R)-1-phenylethyl]amino]carbonyl]propyl]-N4-hydroxy-2-[3-(2-methyl[1,1'-biphenyl]-4-yl)propyl]-butanediamine Chemical Properties
Melting point 93-102oC
density 1.124±0.06 g/cm3(Predicted)
storage temp. Store at -20°C
solubility DMSO: ≥25mg/mL
form powder
pka9.16±0.20(Predicted)
color white to tan
Optical Rotation[α]/D >+25.0°, c = 0.5 in methanol
InChIKeyJJHRUUKMPWUYIB-HVOSOHGQSA-N
SMILESC[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c2ccccc2)CC(=O)NO)C(C)(C)C)c3ccccc3
Safety Information
Hazard Codes Xn
Risk Statements 22
WGK Germany 3
Storage Class11 - Combustible Solids
Hazard ClassificationsAcute Tox. 4 Oral
MSDS Information
N1-[(1S)-2,2-Dimethyl-1-[[[(1R)-1-phenylethyl]amino]carbonyl]propyl]-N4-hydroxy-2-[3-(2-methyl[1,1'-biphenyl]-4-yl)propyl]-butanediamine Usage And Synthesis
UsesPotent and selective inhibitor of matrix metalloprotease-3 (MMP-3) (IC50 = 5.9 nM). Displays selectivity over a range of MMPs (IC50 values are 73, 840, 1790, 1900 and 51000 for MMP-13, MMP-9, MMP-2, MMP-14 and MMP-1 respectively).
DefinitionChEBI: (2R)-N-[(2S)-3,3-dimethyl-1-oxo-1-[[(1R)-1-phenylethyl]amino]butan-2-yl]-N'-hydroxy-2-[3-(3-methyl-4-phenylphenyl)propyl]butanediamide is a secondary carboxamide.
Biological ActivityUK 356618 has the potential to inhibit interleukin (IL)-6-induced cell migration in NCI H446 small cell lung cancer cells in vitro.', 'UK-356,618 is a potent, selective inhibitor of Matrix metalloproteinase MMP3 (stromelysin-1). MMP-3 IC50 = 5.9 nM, selectivity is 140-fold vs MMP-1, -2, -9, and -14.
in vivo

UK 356618 (15 mg/kg; intravenous injection; for 24 h or 7 days; male Wistar rats) treatment at reperfusion significantly reduces MMP3 activity in the brain[3].

Animal Model:Hyperglycemic male Wistar rats injected with middle cerebral artery occlusion (MCAO)[3]
Dosage:15 mg/kg
Administration:Intravenous injection; for 24 h or 7 days
Result:Significantly reduced MMP3 activity in the brain.
IC 50MMP-3: 5.9 nM (IC50); MMP-13: 73 nM (IC50); MMP-9: 0.84 μM (IC50); MMP-2: 1.79 μM (IC50); MMP-14: 1.9 μM (IC50); MMP-1: 51 μM (IC50)
N1-[(1S)-2,2-Dimethyl-1-[[[(1R)-1-phenylethyl]amino]carbonyl]propyl]-N4-hydroxy-2-[3-(2-methyl[1,1'-biphenyl]-4-yl)propyl]-butanediamine Preparation Products And Raw materials
Tag:N1-[(1S)-2,2-Dimethyl-1-[[[(1R)-1-phenylethyl]amino]carbonyl]propyl]-N4-hydroxy-2-[3-(2-methyl[1,1'-biphenyl]-4-yl)propyl]-butanediamine(230961-08-7) Related Product Information
Dihydrocaffeic acid SP-8356 Caffeic acid Ginsenoside CK K122 trifloroacetic acid DC-Y13-27